Methicillin-resistant staphylococcus aureus (MRSA) drugs, such as, Vancomycin, are used to treat most MRSA infections caused by multi-drug resistant strains. MRSA infections are of two types, such as community-associated MRSA infections (CA-MRSA) and hospital-associated MRSA infection (HA-MRSA). It is mainly associated with invasive procedures such as intravenous tubing, surgeries, and through the skin to skin contact (sometimes). Methicillin-resistant staphylococcus aureus (MRSA) drugs are used to kill or restrain MRSA infection. Vancomycin or daptomycin are the agents of choice for treatment of MRSA infections.
Methicillin-resistant staphylococcus aureus is a bacterium group of staph bacteria. Methicillin is a member of the sulfamethoxazole family and is used to cure many staph infection types. MRSA is a specific type of staph bacterium that is resistant to most antibiotics. MRSA is known to cause a number of difficult-to-treat medical conditions in humans, especially those that involve staph spread. The most common symptoms of MRSA are skin lesions, fever, chills, diarrhea, and vomiting. It is important for doctors to recognize and diagnose MRSA when it is found within a patient's body. The greatest threat from MRSA is its ability to develop resistance to most antibiotics like methicillin within a short period of time.
MRSA infections are usually resistant to several types of antibiotics including tetracycline, doxycycline, amoxicillin, cefuroxime, minocycline, and erythromycin. If MRSA takes hold in a person's body, then other drugs like doxycycline, azithromycin, and chloramphenicol are not capable of clearing up the infection. MRSA refers to a set of Gram-negative bacteria which are very genetically different from other known strains of Staphylococcus. MRSA is the cause of many hard-to-treat acute infections in people. In addition, the drug resistance develops due to genetic differences and exposure to various antibiotics like amoxicillin, penicillin, cephalexin, and streptomycin. The drug-resistant strains are proving increasingly difficult to control and are prone to all types of opportunistic infections.
MRSA infections are highly associated with healthcare settings where there is great use of broad spectrum antibiotics. Patients with MRSA infections have a difficult time recovering from their infection and often require round-the-clock treatment. As the staph bacteria are becoming resistant to methicillin, many health care workers who have been infected with MRSA have developed life-threatening infections such as sepsis, amoebiasis, and meningitis. MRSA infections have become such a serious threat that most hospitals and medical centers are now implementing policies that require physicians to refuse or limit the use of methicillin if there is a situation of resistance.
Various antibacterial agents or methicillin-resistant staphylococcus aureus (MRSA) drugs, such as tedizolid phosphate, clindamycine, tetracycline, ceftaroline fosamil, daptomycin, and vancomycin are available in the market for treatment of infections associated with MRSA. Of which, vancomycin is widely used to treat MRSA infections caused by multi-drug resistant strains. Minocycline, fluoroquinolones, co-trimoxazole, or clindamycin may be useful when patients do not have life-threatening infections caused by strains susceptible to these agents. Treatment of MRSA at home usually includes a 7 to 10 day course of an antibiotic (by mouth) such as doxycycline, linezolid, minocycline, clindamycin, or trimethoprim-sulfamethoxazole.
No comments:
Post a Comment